StreetAlpha.app
Home › Stocks › XERS

Xeris Biopharma Holdings, Inc. (XERS)

Healthcare
$16.97
▲ +2.11%
LAST CLOSE · NOV 20

Xeris is a biopharmaceutical company in Chicago that sells medicines for rare endocrine and neurological diseases. It last closed at $16.97 on Nov 20, up 2.11% on the day. The next earnings report for XERS is expected around Mon, Mar 1, 2027. For the quarter ended Sep 2026, XERS reported EPS of $0.06 on revenue of $107.2M, with revenue up 44.2% from a year ago. Over its last 8 reports the stock moved an average of 13.8% the session after earnings. Over the last 12 months XERS insiders bought $0 of stock on the open market and sold $5.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is XERS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold XERS.

Key Stats

Last 12 months
Results
Revenue
$368.3M
+38.4% vs a year ago
Net income
−$6.5M
−1.8% margin
EPS (diluted)
−$0.03
Operating margin
12.7%
$46.8M operating income
Valuation
Market cap
$3.1B
182.7M shares
P/E
–
No P/E while losing money
Price to sales
8.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$131.1M
At Sep 30
Debt
$189.7M
At Sep 30
Shareholder equity
$48.8M
Shares outstanding
182.7M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $49.6M$49.6MFY2021FY2022: $110.2M$110.2MFY2022FY2023: $163.9M$163.9MFY2023FY2024: $203.1M$203.1MFY2024FY2025: $291.8M$291.8MFY2025

From XERS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 1
Estimated date · Time not announced
Reported EPS
$0.06
Quarter ended Sep 2026
Year ago EPS
$0.00
Same quarter last year
Revenue
$107.2M
+44.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.03Dec '24Mar 2025: -$0.06Mar '25Jun 2025: -$0.01Jun '25Sep 2025: $0.00Sep '25Dec 2025: $0.07Dec '25Mar 2026: $0.01Mar '26Jun 2026: -$0.18Jun '26Sep 2026: $0.06Sep '26Latest $0.06
Revenue by quarter
Dec 2024: $60.1MDec '24Mar 2025: $60.1MMar '25Jun 2025: $71.5MJun '25Sep 2025: $74.4MSep '25Dec 2025: $85.8MDec '25Mar 2026: $83.1MMar '26Jun 2026: $92.1MJun '26Sep 2026: $107.2MSep '26Latest $107.2M
How XERS moved after its last 8 reports
Average move the session after a report ±13.8%
Nov 5, 2026Time not announced+25.1%
Aug 6, 2026Time not announced−9.3%
May 7, 2026Time not announced+4.1%
Mar 2, 2026Time not announced−1.6%
Jan 8, 2026Time not announced+12.8%
Nov 6, 2025Time not announced−21.9%
Aug 7, 2025Time not announced+20.2%
May 8, 2025Time not announced+15.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on XERSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on XERS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on XERS

Technical Analysis

XERS · as of the Nov 20 close · updated each morning
Uptrend, overbought

The stock is 18% above its 20 day and 33% above its 50 day average. It is 52% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 82), overbought. The nearest support is the Pivot at $16.84, and the nearest resistance the Pivot R1 at $17.16.

Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityHigh, 4.1%/day
Key levels
$17.2852 week high+1.8%
$17.16Pivot R1+1.1%
$16.97Last close
$16.84Pivot−0.8%
$16.65Pivot S1−1.9%
$13.8820 day average−18.2%
$11.2950 day average−33.5%
$10.08Swing low (Nov 2)−40.6%
$9.84100 day average−42.0%
$8.07200 day average−52.4%
$5.2552 week low−69.1%
Indicators
RSI (14)81.67Overbought above 70Overbought
MACD1.82Above its signal lineBullish
Stochastic94.2Near the top of its rangeOverbought
ADX (14)53.0Strong uptrend
Williams %R-4.3Oversold below −80, overbought above −20Overbought
CCI (20)73.3Oversold below −100, overbought above 100Neutral
Rate of change+11.6%Change over 10 sessionsBullish
ATR (14)$0.69Typical daily range, 4.1% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for XERS

What happened before

See how XERS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow XERS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How XERS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for XERSHow many large options trades hit XERS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

XERS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲137 buying vs 97 selling
  • ▲Held by funds +2.8 pts
  • ▲Funds holding +10
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding251241+4.1%
In funds' top 10330.0%
Held by funds62.1%59.3%+2.8 pts
New / increased33 / 10434 / 106−2.1%
Reduced / sold out73 / 2465 / 30+2.1%
Put/call ratio0.000.81−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XERS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

XERS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$5.8M33 sales · 9 insiders
78% of the selling was under pre-arranged trading plans.
2025-12 sold $1.2M2026-01 sold $420K2026-02 sold $124K2026-03 sold $164K2026-04 sold $100K2026-05 sold $104K2026-06 sold $503K2026-07 sold $1.2M2026-08 sold $296K2026-09 sold $561K2026-10 sold $345K2026-11 sold $773KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 5Kevin McCullochSee RemarksSale plan25,000$12.49$312K
Nov 2Kevin McCullochSee RemarksSale plan15,000$10.23$153K
Nov 2Beth HechtSee RemarksSale plan25,000$10.23$256K
Nov 2Steven PieperSee RemarksSale plan5,000$10.23$51K
Oct 1Beth HechtSee RemarksSale plan16,666$9.41$157K
Oct 1Kevin McCullochSee RemarksSale plan15,000$9.41$141K
Every insider buy and sale for XERS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See XERS insider trades →

From SEC Form 4 filings by XERS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XERS is in one of them and how their past XERS trades turned out.

XERS in the AI portfolios
Loading…

XERS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XERS in an article yet. Here's the latest on the wider market.

XERS in the news

About Xeris Biopharma Holdings

Xeris is a biopharmaceutical company based in Chicago, Illinois, that develops and sells medicines for chronic endocrine and neurological diseases in the United States. Its marketed products include Recorlev for Cushing's syndrome, Gvoke, a glucagon treatment for severe low blood sugar, and Keveyis for primary periodic paralysis. Its customers include patients and the clinicians who treat them, and it is developing a weekly injectable form of levothyroxine for hypothyroidism.

Headquarters
Chicago, IL